Expert analysis
Analysts deliver insights on the trends influencing drug pipelines, mergers and acquisitions, drug pricing, and more.
Access analyst-led insights on the key investments, partnerships, and market shifts shaping pharma and biotech following JPM 2027.
The JPM Healthcare Conference sets the tone for the healthcare investment year. But between hundreds of presentations, deal rumours and side meetings, the signals that matter are easy to miss.
Our post-conference report distils the conference's key insights through a GlobalData lens, highlighting major biopharma trends, dealmaking activity and notable developments across therapy areas to provide a clear perspective on the outlook for 2027.
Analysts deliver insights on the trends influencing drug pipelines, mergers and acquisitions, drug pricing, and more.
Exclusive analysis across pipelines, clinical trials, and deal activity, enriched by GlobalData datasets.
Clear explanation of company strategies and their healthcare impact in 2027, designed for executive leadership, strategy, BD&L, and R&D teams.
Proprietary data, expert analysis, and purpose-built AI connected in a single decision engine, giving you clarity on what’s coming and why it matters.
3,000 in-house subject matter experts and unrivalled datasets providing a complete, connected view of the healthcare landscape.
AI-powered intelligence that reduces time from insight to decision, helping 5,000+ organizations move faster, de-risk choices, and lead with confidence.
Pre-register for our post-conference report here.
We'll send you the report as soon as it's published so that you're the first to download our analysts' insights into the biggest strategic considerations for 2027.